BONE DENSITY PARAMETERS CHANGING IN POSTMENOPAUSAL WOMEN WITH DIFFUSE SITES NONTOXIC GOITER AND AUTOIMMUNE THYROIDITIS IN TREATMENTLOW-DOSE ESTROGEN-PROGESTOGENS MEDICATION

Postmenopausal osteoporosis - multifactorial disease, on the pathogenesis of which affect not only the estrogen deficiency, but functional state of other endocrine glands, particularly the thyroid gland. The article presents the results of a research 74 women with autoimmune thyroiditis and diffuse nodular nontoxic goiter, which during perimenopause and menopause for 12 months received low-dose estrogen-progestin preparation containing 2 mg drospirenone and 1 mg of 17-estradiol. The control group consisted of 40 women of similar age without thyroid disease who were not receiving drugs hormone replacement therapy (HRT). To study the effect of HRT on bone metabolism all women at baseline and after 12 months of follow-conducted study of bone mineral density (BMD) with dual en ergy X-ray absorptiometry (DXA). As a result of the treatment received reliable increase in BMD in the lumbar spine L1-L4 9-10% (p <0.001) in the proximal femur - by 2.8-3.5% (p <0.01) in the bones forearm - by 1.8-2.1% (p <0.01).Conclusion: The use of low-dose estrogen-progestin drugs for 12 months in women with autoimmune thyroiditis and diffuse nodular nontoxic goiter in peri- and postmenopausal period helped gain in BMD in both trabecular and cortical bone structure.

postmenopausal osteoporosis, osteopenia, menopause, hypothyroidism, autoimmune thyroiditis, diffuse nodular nontoxic goiter, hormone replacement therapy